Dr. Raymond Douglas, MD, PhD
Raymond Douglas, MD, PhD, is a world-renowned, board-certified aesthetic and reconstructive oculoplastic surgeon in Beverly Hills, California. He’s an international authority in aesthetic and reconstructive oculoplastic surgery, specializing in Thyroid Eye Disease (TED) treatment and transformations. He is one of the lead scientists in the development of the only FDA approved treatment for TED (Tepezza) and has pioneered multiple techniques in aesthetic TED transformation. Dr. Douglas has spent the last 20 years understanding, researching, and treating oculoplastic conditions including thyroid eye disease (TED). With his team of medical experts, Dr. Douglas pioneered breakthrough research, understanding the pathways involved in TED, and leading to the identification of Tepezza. He was the principal investigator of the international clinical trials that led to FDA approval, and the first person in the world to treat patients with Tepezza following its approval by the FDA. Dr. Douglas is President and CEO of Thrive Health, a full service infusion center offering patient centered, concierge care specializing in Tepezza. He's also a professor at Cedars Sinai Hospital in Los Angeles where he is head of the orbital and TED programs.
Dr. Raymond Douglas, MD, PhD
Raymond Douglas, MD, PhD, is a world-renowned, board-certified aesthetic and reconstructive oculoplastic surgeon in Beverly Hills, California. He’s an international authority in aesthetic and reconstructive oculoplastic surgery, specializing in Thyroid Eye Disease (TED) treatment and transformations. He is one of the lead scientists in the development of the only FDA approved treatment for TED (Tepezza) and has pioneered multiple techniques in aesthetic TED transformation. Dr. Douglas has spent the last 20 years understanding, researching, and treating oculoplastic conditions including thyroid eye disease (TED). With his team of medical experts, Dr. Douglas pioneered breakthrough research, understanding the pathways involved in TED, and leading to the identification of Tepezza. He was the principal investigator of the international clinical trials that led to FDA approval, and the first person in the world to treat patients with Tepezza following its approval by the FDA. Dr. Douglas is President and CEO of Thrive Health, a full service infusion center offering patient centered, concierge care specializing in Tepezza. He's also a professor at Cedars Sinai Hospital in Los Angeles where he is head of the orbital and TED programs.